The European Commission's Green Deal is an opportunity to rethink harmful practices of research and innovation policy

The European Union's Green Deal and associated policies, aspiring to long-term environmental sustainability, now require economic activities to 'do no significant harm' to EU environmental objectives. The way the European Commission is enacting the do no significant harm principle relies on quantitative tools that try to identify harm and adjudicate its significance. A reliance on established technical approaches to assessing such questions ignores the high levels of imprecision, ambiguity, and uncertainty-levels often in flux-characterizing the social contexts in which harms emerge. Indeed, harm, and its significance, are relational, not absolute. A better approach would thus be to acknowledge the relational nature of harm and develop broad capabilities to engage and 'stay with' the harm. We use the case of European research and innovation activities to expose the relational nature of harm, and explore an alternative and potentially more productive approach that departs from attempts to unilaterally or uniformly claim to know or adjudicate what is or is not significantly harmful. In closing, we outline three ways research and innovation policy-makers might experiment with reconfiguring scientific and technological systems and practices to better address the significant harms borne by people, other-than-human beings, and ecosystems.

What funders are doing to assess the impact of their investments in health and biomedical research

As pressures to maximize research funding grow, biomedical research funders are increasingly tasked with demonstrating the long-term and real-world impacts of their funded research investments. Over the past three decades, research impact assessments (RIA) have emerged as an important tool for analysing the impacts of research by incorporating logic models, frameworks and indicators to track measures of knowledge production, capacity-building, development of research products, adoption of research into clinical guidelines and policies, and the realization of health, economic and social benefits. While there are currently several models for RIA within the literature, less attention has been paid to how funders can practically select and implement a RIA model to demonstrate the impacts of their own research portfolios. In this paper, a literature review was performed to understand (1) which research funders have performed RIAs of their research portfolios to date; (2) how funders have designed their assessments, including the models and tools they have used; (3) what challenges to and facilitators of success have funders found when adopting the RIA model to their own portfolio; and (4) who participates in the assessments. Forty-four papers from both published and grey literature were found to meet the review criteria and were examined in detail. There is a growing culture of RIA among funders, and included papers spanned a diverse set of funders from 10 countries or regions. Over half of funders (59.1%) used a framework to conduct their assessment, and a variety of methods for collecting impact data were reported. Issues of methodological rigour were observed across studies in the review, and this was related to numerous challenges funders faced in designing timely RIAs with quality impact data. Over a third of articles (36.4%) included input from stakeholders, yet only one article reported surveying patients and members of the public as part of the assessment. To advance RIA among funders, we offer several recommendations for increasing the methodological rigour of RIAs and suggestions for future research, and call for a careful reflection of the voices needed in an impact assessment to ensure that RIAs are having a meaningful impact on patients and the public.